PSN1细胞

PSN1细胞PSN1细胞系PSN1人胰腺癌细胞

Cell line name PSN1

Synonyms PSN-1

Accession CVCL_1644

Resource Identification Initiative To cite this cell line use: PSN1 (RRID:CVCL_1644)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: KuDOS 95 cell line panel.

Part of: MD Anderson Cell Lines Project.

Population: Japanese.

Characteristics: Established from a frozen tumor that had been stored at -80 Celsius for 1.5 years and which has then been passaged into a nude mice.

Doubling time: 21 hours (PubMed=3778442); 35 hours (PubMed=25984343).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Metabolome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.

Sequence variations

Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=11787853).

Gene deletion; HGNC; HGNC:6770; SMAD4; Zygosity=Homozygous (PubMed=11787853; PubMed=18380791).

Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (PubMed=3778442; PubMed=11787853; Cosmic-CLP=910546; DepMap=ACH-000320).

Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys132Gln (c.394A>C); ClinVar=VCV000376628; Zygosity=Homozygous (PubMed=1764370; PubMed=11787853; Cosmic-CLP=910546; DepMap=ACH-000320).

HLA typing Source: PubMed=26589293

Class I

HLA-A A*24:02,24:02

HLA-B B*52:01,52:01

HLA-C C*12:02,12:02

Class II

HLA-DR DRB1*15:02,15:02

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 0

Native American 0

East Asian, North 83.56

East Asian, South 16.44

South Asian 0

European, North 0

European, South 0

Disease Pancreatic adenocarcinoma (NCIt: C8294)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Hierarchy Children:

CVCL_2451 (GR-M)

Sex of cell Male

Age at sampling Age unspecified

Category Cancer cell line

STR profile Source(s): AddexBio=C0018013/4990; ATCC=CRL-3211; Cosmic-CLP=910546; PubMed=25877200

 

Markers:

Amelogenin X

CSF1PO 12

D3S1358 15,17

D5S818 11,13

D7S820 10

D8S1179 10,14

D13S317 10

D16S539 10,11 (AddexBio=C0018013/4990; ATCC=CRL-3211; PubMed=25877200)

11 (Cosmic-CLP=910546)

D18S51 21

D21S11 29,30

FGA 23

Penta D 9,12

Penta E 14,15

TH01 6

TPOX 8,11

vWA 17

 

Run an STR similarity search on this cell line

Publications

PubMed=3009377; DOI=10.20772/cancersci1985.77.4_370

Yamada H., Sakamoto H., Taira M., Nishimura S., Shimosato Y., Terada M., Sugimura T.

Amplifications of both c-Ki-ras with a point mutation and c-myc in a primary pancreatic cancer and its metastatic tumors in lymph nodes.

Jpn. J. Cancer Res. 77:370-375(1986)

 

PubMed=3778442; DOI=10.1016/0006-291X(86)91072-7

Yamada H., Yoshida T., Sakamoto H., Terada M., Sugimura T.

Establishment of a human pancreatic adenocarcinoma cell line (PSN-1) with amplifications of both c-myc and activated c-Ki-ras by a point mutation.

Biochem. Biophys. Res. Commun. 140:167-173(1986)

 

PubMed=1764370; DOI=10.1038/bjc.1991.467; PMCID=PMC1977874

Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C., Kloppel G., Theis B., Russell R.C.G., Neoptolemos J., Williamson R.C.N., Lane D.P., Lemoine N.R.

Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer.

Br. J. Cancer 64:1076-1082(1991)

 

PubMed=11787853; DOI=10.1007/s004280100474

Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R., Gress T.M., Bassi C., Kloppel G., Kalthoff H., Ungefroren H., Lohr J.-M., Scarpa A.

Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.

Virchows Arch. 439:798-802(2001)

 

PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x; PMCID=PMC11158928

Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A., Shiratori K., Hirohashi S., Inazawa J., Imoto I.

Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.

Cancer Sci. 99:986-994(2008)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

 

PubMed=25167228; DOI=10.1038/bjc.2014.475; PMCID=PMC4453732

Hamidi H., Lu M., Chau K., Anderson L., Fejzo M.S., Ginther C., Linnartz R., Zubel A., Slamon D.J., Finn R.S.

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.

Br. J. Cancer 111:1788-1801(2014)